StockNews.com Begins Coverage on Pulmatrix (NASDAQ:PULM)

Stock analysts at StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM) in a research report issued to clients and investors on Friday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Price Performance

PULM stock opened at $5.91 on Friday. The business has a fifty day moving average price of $4.21 and a 200 day moving average price of $2.81. Pulmatrix has a fifty-two week low of $1.55 and a fifty-two week high of $8.44. The stock has a market capitalization of $21.58 million, a price-to-earnings ratio of -2.24 and a beta of 1.54.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.